Summary
A cyclophosphamide-resistant subline of a Yoshida ascites tumor was developed by giving increasing doses of the drug after transplantation. The effect of several alkylating agents on the cell proliferation of both the sensitive and resistant cell line was compared establishing dose response curves and D50 values.
The developed subline revealed a 260 fold resistance to cyclophosphamide. It was completely cross-resistant to hydroperoxycyclophosphamide, whereas for triaziquone, N-oxide-mustard, and N-methyl-mustard only a partial cross resistance existed.
These results give further evidence that cyclophosphamide and hydroperoxycyclophosphamide have the same mechanism of action. Regarding the other alkylating agents the results demonstrate differences concerning either the molecular mode of action or protecting effects. A decreased activation or uptake of substance is probably not the base for resistance.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ball, C.R., Connors, T.A., Cooper, E.H., Topping, N.E.: Comparison of nitrogen mustard sensitive and resistant Yoshida sarcomas. Effect of tretment on cell kinetics. Neoplasma 14, 253–264 (1967)
Bender, R.A., Dedrick, R.L.: Cytokinetic aspects of clinical drug resistance. Cancer Chemother. Rep. 59, 805–809 (1975)
Brock, N., Hohorst, H.J. Über die Aktivierung von Cyclophosphamid in vivo und in vitro. Arzneimittel Forsch. 13, 1021–1031 (1963)
Chun, E.H.L., Gonzales, L., Leon, F.S., Jones, J., Rutman, R.J.: Differences in the in vivo alkylation and cross-linking of nitrogen mustard sensitive and resistant lines of Lettré-Ehrlich ascites tumors. Cancer Res. 29, 1184–1194 (1969)
Connors, T.A.: Alkylating agenets. In: Topics of current chemistry (ed.: Boschke, F.), Vol. 52, p. 141–171 Berlin, Heidelberg, New York: Springer 1974
Connors, T.A., Cox, P.J., Farmer, P.B., Foster, A.B., Jarman, M.: Some studies of the active intermediates formed in the microsomal metabolism of Cyclophosphamide and Iphosphamide. Biochem. Pharmacol. 23, 115–129 (1974)
Cox, P.J., Phillips, B.J., Thomas, P.: The enzymatic basis of the selective action of Cyclophosphamide. Cancer Res. 35, 3755–3761 (1975)
Domeyer, B.E., Sladek, N.E.: Potential for in vivo inactivation of a Cyclophosphamide metabolite (Aldophosphamide) by tumor enzymes. Fed. Proc. 33, 581 (1974)
Draeger, H., Hohorst, H.J.: Permeation of Cyclophosphamide (NSC 26271) metabolites into tumor cells. Cancer Treat. Rep. 60:423–427 (1976)
Draeger, U., Peter, G., Hohorst, H.J.: Deactivation of Cyclophosphamide (NSC 26271) metabolites by sulfhydryl compounds. Cancer Treat. Rep. 60, 355–359 (1976)
Gaudin, D.A., Yielding, K.L.: Response of a resistant plasmocytoma to alkylating agents and X-ray in combination with the excision repair inhibitors Caffeine and Chloroquine. Proc. Soc. Exp. Biol. Med. 131, 1413–1416 (1969)
Harrap, K.R., Hill, B.T.: The selectivity of action of alkylating agents and drug resistance. Br. J. Cancer 23, 210–225 (1969)
Hill, B.T.: Differential effects of cytotoxic concentrations of chlorambucil on drug-resitant and drugsensitive lines of the Yoshida ascites sarcoma in culture. Eur. J. Cancer 11, 9–16 (1975)
Hutchinson, D.J.: Studies on cross resistance and collateral sensitivity. Cancer Res. 25, 1581–1594 (1965)
Liss, E., Reinecke, A., Palme, G.: Die Hemmung der DNS-Synthese und die Beeinflussung der Zellvermehrung von Yoshida-Ascitestumorzellen durch alkylierende Substanzen. Arzneimittel Forsch. 19, 1137–1140 (1969)
Schmidt, H., Liss, E.: Different uptake of two alkylating substances by ascites tumor cells. Arzneimittel Forsch. 28, 2150–2152 (1978)
Seidel, H.J., Wegner, L.A.: Zur Sensibilitätsbestimmung von Tumoen in vitro. Z. Krebsforsch. 72, 105–118 (1969)
Sladek, N.E.: Bioassay and relative cytotoxic potency of Cyclophosphamide metabolites generated in vitro and in vivo. Cancer Res. 33, 1150–1158 (1973)
Takamizawa, A., Matsumoto, S., Iwata, T., Katagiri, K., Tochino, Y., Yamaguchi, K.: Studien on Cyclophosphamide metabolites and their related compounds. II. Preparation of an active species of Cyclophosphamide and some related compounds. J. Am. Chem. Soc. 95, 985–986 (1973)
Voelcker, G., Draeger, U., Peter, G., Hohorst, H.J.: Studien zum Spontanzerfall von 4-Hydroxycyclophosphamid und 4-Hydroperoxycyclphosphamid mit Hilfe der Dünnschichtchromatographie. Arzneimittel Forsch. 24, 1172–1176 (1974)
Voelcker, G., Wagner, T., Hohorst, H.J.: Identification and pharmacocinetics of Cyclophosphamide (NSC 26271) metabolites in vivo. Cancer Treat. Rep. 60, 415–422 (1976)
Volm, M., Bastert, G., Mattern J., Wayss, K.: Onkobiogramm und Therapieerfolg bei Transplantationstumoren. Naturwissenschaften 60, 395 (1973)
Wolpert, M.K., Ruddon, R.W.: A study on the mechanism of resistance to HN 2 in Ehrlich ascites tumor cells: Comparison of uptake of HN2. Cancer Res. 29, 873–879 (1969)
Yin, L., Chun, E.H.L., Rutmann, R.J.: A comparison of the effects of alkylation on the DNA of sensitive and resistant Lettré-Ehrlich cells following in vivo exposure to nitrogen mustard. Biochim. Biophys. Acta 324, 472–482 (1973)
Author information
Authors and Affiliations
Additional information
Supported by Bundesministerium für Forschung und Technologie
Rights and permissions
About this article
Cite this article
Gerhartz, H.H., Liss, E. & Schmidt, H. Cyclophosphamide-resistant Yoshida ascites tumor cells and their cross resistance to some alkylating agents. J Cancer Res Clin Oncol 94, 257–263 (1979). https://doi.org/10.1007/BF00419285
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00419285